Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022


Print article Print article
2013-12-10 09:45:59 - Recently published research from GlobalData, "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022", is now available at Fast Market Research

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

The growth in the US SLE and LN therapeutics will be driven by higher uptake of existing biologic drugs and the launch of new biologics, expanded access to medical care as a

result of healthcare reforms and the increasing prevalent cases of SLE and LN.

Full Report Details at
- www.fastmr.com/prod/752894_pharmapoint_systemic_lupus_erythemato ..

Scope

* Overview of SLE-LN including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in US including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in US from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting US SLE-LN market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in US

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms
4 Disease Management
4.1 Diagnosis Overview
4.1.1 SLE Diagnosis
4.1.2 LN Diagnosis
4.2 Treatment Overview
4.3 US
4.3.1 Diagnosis
4.3.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Antimalarial Therapy (numerous brand names)
5.3.2 Steroids (numerous brand names)
5.3.3 Methotrexate (numerous brand names)
5.3.4 Mycophenolate Mofetil (numerous brand names)
5.3.5 Cyclophosphamide (numerous brand names)
5.3.6 Azathioprine (numerous brand names)
5.3.7 Calcineurin Inhibitors (numerous brand names)
5.3.8 Benlysta (belimumab)
5.3.9 Rituxan (rituximab)
5.3.10 Minor Therapeutic Classes
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Efficacious Treatments with Reduced Side Effects
6.2.2 Management of LN
6.2.3 Improvement in Patients' Mortality
6.2.4 Management of Lupus Comorbidities
6.2.5 Sensitive and Reliable Biomarkers
6.2.6 Physicians' Education and Public Awareness of SLE
6.2.7 Unmet Needs Gap Analysis
6.3 Opportunities
6.3.1 Efficacious and Safe Therapies
6.3.2 Therapies Targeting LN Patients
6.3.3 Treatments for Common Lupus Comorbidities
6.3.4 Discovery of Biomarkers
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Blisibimod (A-623)
7.2.2 Tabalumab (LY-2127399)
7.2.3 Atacicept
7.2.4 Epratuzumab
7.2.5 Lupuzor (rigerimod)
7.2.6 Orencia (abatacept)
8 Market Outlook
8.1 US
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed SLE and LN Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analysts
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of SLE
Table 2: 1997 Updated ACR Criteria for Classification of SLE
Table 3: The SLICC Clinical and Immunologic Criteria for Classification of SLE
Table 4: WHO and ISN/RPS classifications of LN
Table 5: Treatment Guidelines for SLE and LN
Table 6: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2013
Table 7: Leading Treatments for SLE and LN, 2013
Table 8: Product Profile - Hydroxychloroquine
Table 9: Antimalarial Therapy SWOT Analysis, 2013
Table 10: Product Profile - Steroids
Table 11: Steroids SWOT Analysis, 2013
Table 12: Product Profile - Methotrexate

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=752894&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com